FDA Adverse Event Injury Summary report: N

PIPELINE

MDR report key: 13518807 · Received February 11, 2022

Report

Report Number
2029214-2022-00208
Event Type
Injury
Date Received
February 11, 2022
Date of Event
October 21, 2021
Report Date
February 11, 2022
Manufacturer
MICRO THERAPEUTICS, INC. DBA EV3
Product Code
OUT
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

LI X-Y, LI C-H, WANG J-W, LIU J-F, LI H, GAO B-L. ENDOVASCULAR MANAGEMENT OF CEREBRAL ANEURYSMS OF THE POSTERIOR CEREBRAL ARTERY. FRONTIERS IN NEUROLOGY. 2021;12:700516. DOI:10.3389/FNEUR.2021.700516. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 0

LI X-Y, LI C-H, WANG J-W, LIU J-F, LI H, GAO B-L. ENDOVASCULAR MANAGEMENT OF CEREBRAL ANEURYSMS OF THE POSTERIOR CEREBRAL ARTERY. FRONTIERS IN NEUROLOGY. 2021;12:700516. DOI:10.3389/FNEUR.2021.700516. MEDTRONIC LITERATURE REVIEW FOUND A REPORT OF PATIENT COMPLICATIONS IN ASSOCIATION WITH A PIPELINE DEVICE. THE PURPOSE OF THIS ARTICLE WAS TO INVESTIGATE THE SAFETY AND EFFICACY OF ENDOVASCULAR EMBOLIZATION OF CEREBRAL ANEURYSMS AT THE P1¿P3 SEGMENTS OF THE POSTERIOR CEREBRAL ARTERY (PCA). SEVENTY-SEVEN PATIENTS WERE TREATED, INCLUDING COILING ALONE IN 10 PATIENTS, STENT-ASSISTED COILING IN 18, PARENT ARTERY OCCLUSION IN 25, AND PIPELINE EMBOLIZATION DEVICE (PED) IN 24. OF THE 77 PATIENTS, 42 WERE MALE AND THE MEAN AGE WAS 53.2 YEARS. THE ARTICLE DOES NOT STATE ANY TECHNICAL ISSUES DURING USE OF THE PIPELINE DEVICE, AND ALL PATIENTS WERE SUCCESSFULLY TREATED ENDOVA SECULARLY. THE FOLLOWING INTRA- OR POST-PROCEDURAL OUTCOMES WERE NOTED: -DURING THE PERIPROCEDURAL PERIOD, TWO PED PATIENTS EXPERIENCED ACUTE THROMBUS FORMATION. THERE WERE NO SEQUELAE AFTER IMMEDIATE THROMBOLYSIS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
60704 PIPELINE INTRACRANIAL ANEURYSM FLOW DIVERTER OUT MICRO THERAPEUTICS, INC. DBA EV3 NV UNK PIPELINE UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1 53 YR Male Required Intervention